#United States #Phoenix, Arizona #Cardiomyopathy #Heart Failure Society of America #late-breaking trials

HFSA 2026 Annual Scientific Meeting: A New Era in Heart Failure Treatment

The Heart Failure Society of America (HFSA) will hold its Annual Scientific Meeting from October 9-12, 2026, at the Phoenix Convention Center in Arizona. This year's agenda promises exciting insights through late-breaking clinical trials that address critical aspects of heart failure treatment, particularly for patients with cardiomyopathy.

Late-Breaking Clinical Research Unveiled

The meeting will showcase pioneering research focusing on pharmacotherapy, imaging, diagnostics, and device therapy in heart failure management. Attendees can anticipate significant findings, including the evaluation of a novel oral therapy aimed at enhancing treatment options for both HFrEF (Heart Failure with Reduced Ejection Fraction) and HFpEF (Heart Failure with Preserved Ejection Fraction).

Jennifer Thibodeau, MD, MSCS, chair of the program committee, stated, “This year's late-breaking science reflects the rapid innovations transforming heart failure care. These trials bring forth advances in multiple facets of treatment and offer some of the most awaited results in cardiovascular medicine.”

The agenda features two plenary sessions, with highlights from pivotal randomized trials.

Key Trials to Be Discussed

1. Cycle-1 REF Trial: This Phase 2 trial investigates the safety and effectiveness of Tovinontrine for chronic heart failure with reduced ejection fraction, building promising outcomes for patients.
2. Cycle-2 PEF Trial: Evaluating Tovinontrine in patients with chronic heart failure with preserved ejection fraction, this study seeks to broaden treatment options available to clinicians.
3. CARDIO-TTRansform Trial: Focused on transthyretin amyloid cardiomyopathy, this trial examines how Eplontersen influences health status in patients.

In addition to these main trials, the meeting will present insights from a Phase 3 study on a novel imaging method designed to detect early cardiac amyloidosis without invasive procedures, indicating a potential shift in diagnostic approaches. Furthermore, real-world outcomes from established device therapies will be shared, providing vital context on the effectiveness of existing treatments.

Rapid Fire Oral Sessions for Dynamic Insights

Due to the extensive and high-quality research submitted, HFSA will also host Rapid Fire Oral Sessions during the meeting. These sessions will consist of quick-paced presentations spotlighting key data from late-breaking clinical research, offering an opportunity for immediate engagement and discussion.

Noteworthy topics include:

• - Cardiac Contractility Modulation Therapy: Findings on the real-world clinical outcomes post-therapy.
• - Baroreflex Activation Therapy: Investigating real-world benefits on hospitalization metrics for patients with heart failure.
• - Early Intervention Strategies: Research indicating associations between early eGFR decline and cardiovascular hospitalizations will be discussed.

Registration and Access for Media

Members of the media interested in covering the meeting can register for complimentary press access through HFSA's official channels. Access to embargoed press materials and opportunities for pre-embargo interviews with researchers will also be available, ensuring stakeholders can prepare comprehensive coverage of this innovative meeting.

The HFSA Annual Scientific Meeting is poised to not only shape current knowledge and approaches to heart failure but also foster discussions on the future of cardiovascular medicine, driving forward potential breakthroughs that could lead to more effective treatments.

For ongoing updates and detailed information about the sessions, research outcomes, and registration, prospective attendees and interested parties are encouraged to visit hfsa.org/asm2026. Follow #HFSA2026 on social media for real-time updates from the meeting.

Conclusion

As the HFSA 2026 Annual Scientific Meeting approaches, anticipation grows around the innovative therapies and significant research data set to be presented. With remarkable advances in pharmacotherapy and diagnostics, heart failure treatment stands on the brink of transformation, promising enhanced care and outcomes for patients worldwide.